acelarin

April 1, 2020April 1, 2020

Acelarin Trial Shows Potential in Chemo-resistant Ovarian Cancer, But Study Ending

News

Treatment with Acelarin led to one complete response and two partial responses in heavily pre-treated women with platinum-resistant ovarian cancer, early results from a Phase 2 trial show. Full analysis of the study’s ... Read more

November 27, 2017

First Patients Enroll in Phase 2 Trial of Acelarin as Treatment for Chemo-resistant Ovarian Cancer

News

NuCana has started a Phase 2 clinical trial of its ovarian cancer therapy Acelarin (NUC-1031) by enrolling the first patients in the United States and Britain. It will continue to recruit 64 participants who ... Read more

September 29, 2017September 29, 2017

Acelarin-Paraplatin Combo Shows High Disease Control Rates in Phase 1b Trial for Ovarian Cancer

News

Nearly all ovarian cancer patients enrolled in NuCana‘s Phase 1b trial benefited from the combination of Acelarin (NUC-1031) plus Paraplatin (carboplatin), according to data presented at the recent European Society ... Read more